Abstract: Results from a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease from Italian Sites

 

Abstract: Results from a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease from Italian Sites

Since 2011, denosumab (Dmab) subcutaneous (SC) injection is available as a superior treatment option in patients with bone metastases from solid tumours, compared with zoledronic acid (Zol) administered as an intravenous (IV) infusion. Although Zol was the mainstay treatment for skeletal-related events prevention, Dmab provides an alternative formulation to IV infusions. This Time and Motion study was conducted in Italy to estimate time endpoints associated with Dmab SC and Zol IV use.